Agomelatine (Valdoxan)
What studies of Agomelatine (Valdoxan) found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 2 findings, all C.
2 outcomes rated · see each below
ME/CFS: B May help
Based on the strongest evidence, the randomised trial (low certainty): 3 findings, all B.
4 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: For long COVID, Agomelatine (Valdoxan) might help some people, but research can’t show it yet. For ME/CFS, Agomelatine (Valdoxan) may help, but the evidence is still limited. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- Agomelatine (Valdoxan) · ME/CFS is hereBMay helpImprovement, low certainty
- Agomelatine (Valdoxan) · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Depression1 study · 103 people took Agomelatine (Valdoxan) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design).
Studies with no comparison group103 with outcome data · 8-week follow-up
Depression improved.
The evidence is very uncertain about the effect of agomelatine (Valdoxan) on depression in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
See the 1 study
-
- People in the study
- 103 with outcome data
- Dose
- —
- Outcome
- antidepressant effectiveness of agomelatine assessed by change in HAMD-17 total score at week 8 Hamilton Rating Scale for Depression
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Quality of life1 study · 103 people took Agomelatine (Valdoxan) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design).
Studies with no comparison group103 with outcome data · 8-week follow-up
Quality of life improved.
The evidence is very uncertain about the effect of agomelatine (Valdoxan) on quality of life in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
Combination: Ethyl loflazepate + Agomelatine (Valdoxan) + Mosapride + Pancreatic enzymes (Creon, Zenpep) + Simethicone (Gas-X) + Tegoprazan + Chinese, Japanese and Korean herbal medicine + Acupuncture + Moxibustion1 in the study
Integrative personalized medicine care for adjustment disorder of a post-COVID-19 patient: A CARE-compliant case report. (2024): EQ-5D-5L scores, better (not tested).
Shown, not counted: Agomelatine (Valdoxan) was given together with other treatments.
See the 1 study
-
- People in the study
- 103 with outcome data
- Dose
- —
- Outcome
- Mental and physical components of SF-36 Short Form Survey
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
ME/CFS
Symptoms
Fatigue1 study · 58 people took Agomelatine (Valdoxan) Improvement B
Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (58 in all).
The randomised trial62 randomised · 58 analysed · 12 weeks (phase I) and 24 weeks from enrollment (phase II) · 50 mg/die, u.i.d
Fatigue improved more than in the comparison group.
Agomelatine (Valdoxan) may reduce fatigue in ME/CFS. Improvement · low certainty B
- Some concerns about bias (RoB 2)
- Few people (58 in all)
See the 1 study
-
Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. (2014)
- People in the study
- 62 randomised · 58 analysed
- Dose
- 50 mg/die, u.i.d
- Outcome
- FSS Krupp Fatigue Severity Scale
- Effect
- better (not tested)
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Sleep1 study · 58 people took Agomelatine (Valdoxan) Little or no difference D
Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); the change wasn't shown to be more than chance.
Studies with no comparison group62 randomised · 58 analysed · 12 weeks (phase I) and 24 weeks from enrollment (phase II) · 50 mg/die, u.i.d
No clear change in sleep.
The evidence is very uncertain about the effect of agomelatine (Valdoxan) on sleep in ME/CFS. Little or no difference · very low certainty D
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- The change wasn't shown to be more than chance
See the 1 study
-
Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. (2014)
- People in the study
- 62 randomised · 58 analysed
- Dose
- 50 mg/die, u.i.d
- Outcome
- ESS Epworth Sleepiness Scale
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Overall symptoms1 study · 58 people took Agomelatine (Valdoxan) Improvement B
Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (58 in all).
The randomised trial62 randomised · 58 analysed · 12 weeks (phase I) and 24 weeks from enrollment (phase II) · 50 mg/die, u.i.d
Overall symptoms improved more than in the comparison group.
Agomelatine (Valdoxan) may improve overall symptoms in ME/CFS. Improvement · low certainty B
- Some concerns about bias (RoB 2)
- Few people (58 in all)
See the 1 study
-
Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. (2014)
- People in the study
- 62 randomised · 58 analysed
- Dose
- 50 mg/die, u.i.d
- Outcome
- CGI Clinical Global Impression Severity
- Effect
- better (not tested)
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Quality of life1 study · 58 people took Agomelatine (Valdoxan) Improvement B
Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (58 in all).
The randomised trial62 randomised · 58 analysed · 12 weeks (phase I) and 24 weeks from enrollment (phase II) · 50 mg/die, u.i.d
Quality of life improved more than in the comparison group.
Agomelatine (Valdoxan) may improve quality of life in ME/CFS. Improvement · low certainty B
- Some concerns about bias (RoB 2)
- Few people (58 in all)
See the 1 study
-
Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. (2014)
- People in the study
- 62 randomised · 58 analysed
- Dose
- 50 mg/die, u.i.d
- Outcome
- SF-12 SF-12 health survey
- Effect
- better (not tested)
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Studies of combinations
Outcomes that only studies of Agomelatine (Valdoxan) given together with other treatments looked at. Shown, not graded: they can’t tell what Agomelatine (Valdoxan) did alone.
Autonomic symptoms Long COVID
Combination: Ethyl loflazepate + Agomelatine (Valdoxan) + Mosapride + Pancreatic enzymes (Creon, Zenpep) + Simethicone (Gas-X) + Tegoprazan + Chinese, Japanese and Korean herbal medicine + Acupuncture + Moxibustion1 in the study
Integrative personalized medicine care for adjustment disorder of a post-COVID-19 patient: A CARE-compliant case report. (2024): autonomic nervous system activity score, better (not tested).
Shown, not counted: Agomelatine (Valdoxan) was given together with other treatments.
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
25 to 50 mg at the start
- 2Top dose
Most often 25 mg (1 of 2 studies)
Doses across 2 studies
25 to 50 mg.
Each study’s dose, as printed
- 50 mg/die, u.i.d Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. (2014)
- 25 mg/day, for 4 weeks; 25 mg/day for ten more weeks for tapering the dosage Integrative personalized medicine care for adjustment disorder of a post-COVID-19 patient: A CARE-compliant case report. (2024)
All papers
- Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study.2014 · randomised trial · 62 randomised · 58 analysed
Summary
This longitudinal proof-of-concept study asked whether agomelatine affects fatigue in people with Chronic Fatigue Syndrome (CFS) and compared it with melatonin to separate melatonin-receptor agonism from 5HT2C antagonism. Sixty-two subjects with CFS were recruited through clinician referrals and self-referrals and randomized to agomelatine 50 mg/die or sustained release melatonin 10 mg/die for 12 weeks (phase I). At week 12, melatonin-treated subjects were switched to agomelatine and re-evaluated after 12 more weeks, i.e. after 24 weeks from enrollment (phase II). Evaluations used the Krupp Fatigue Severity Scale (FSS), Clinical Global Impression Severity (CGI-S), SF-12, Hospital Anxiety and Depression Scale (HADS), Epworth Sleepiness Scale (ESS) and the Frequency, Intensity, and Burden of Side Effects Rating Scale (FIBSER). Four subjects out of 62 were not available at week 12 and discontinued during phase one (three in the melatonin group and one in the agomelatine group); full data were available for the remaining 58 subjects. The paper reports a significant reduction of perceived fatigue on FSS and CGI and an increase in perceived quality of life on SF-12 with agomelatine but not with melatonin. The switch from melatonin to agomelatine was associated with reduced fatigue levels and increased perceived quality of life. There were no statistically significant differences in side-effect perception between groups at the end of phase I, and the switch was not associated with a significant change in FIBSER scores; agomelatine was well tolerated by all enrolled subjects.
- The effectiveness and tolerability of agomelatine in the treatment of depression after COVID-19 infection in Russian daily clinical practice (TELESPHOR study)2024 · no comparison group · 103 with outcome data
Summary
This multicenter, observational study enrolled outpatients with a major depressive episode after laboratory-confirmed SARS-CoV-2 infection who had started agomelatine. The full analysis set comprised 103 patients. There was no comparison group and the study was not randomised. Treatment was followed over an 8-week follow-up, with visits at weeks 2, 4 and 8. The primary outcome was change in HAMD-17 total score at week 8. Mean total HAMD-17 score decreased compared with baseline by 2.6±3.3, 6.7±5.3 and 10.9±4.9 at weeks 2, 4 and 8, respectively (P<0.0001 for all). Significant reductions in HAMD-17 anxiety psychic and anxiety somatic items were also reported. Mental and physical SF-36 components improved compared with baseline (P<0.0001). The proportion of responders was 81.4% and the proportion of remitters was 71.6%. The abstract states agomelatine was well tolerated over the 8-week follow-up; no side-effect counts, withdrawals or limitations were reported.
- Integrative personalized medicine care for adjustment disorder of a post-COVID-19 patient: A CARE-compliant case report.2024 · combination: given with other treatments · 1 in the study
Summary
This CARE-compliant case report describes one 84-year-old female patient with adjustment disorder of post-COVID-19 syndrome who visited a traditional Korean Medicine hospital in Seoul, Republic of Korea, in August 2023. There was no comparison group. Treatment was integrative personalized medicine care: conventional Western drugs (ethyl loflazepate, agomelatine, mosapride, pancreatin, simethicone, tegoprazan), herbal medicines (Chowiseungcheong-tang, Cheongsimyeonja-tang, Bosimgunbi-tang, Cheonghyulganggi-tang), acupuncture (18 sessions, 20 minutes each) and moxibustion. The patient had a 10-day inpatient treatment followed by outpatient treatments 2 to 3 times a week after discharge. Assessments were at week 1, week 7 and week 16 from start of treatment. HAM-D scores decreased from 13 to 3 at week 7; BDI from 27 to 5 at week 7 and from 5 to 4 at week 16; Patient Health Questionnaire-9 from 20 to 1 at week 7 and week 16; ISI from 23 to 5 at week 7. Sleep changed from taking 1 to 3 hours to fall asleep and waking 5 to 6 times to 8 hours of restful sleep on the day of taking CSYJ-tang. EQ-5D-5L changed from 7 to 0 and EQ-VAS from 50 to 90 at week 16. HRV score changed from 62 to 73, and was 71 at follow-up on November 7, 2023. Gastrointestinal symptoms and palpitations disappeared. Harms and withdrawals for harms were not reported. The authors state limitations including no polysomnography, thyroid test, or vitamin B12 test.